Global Respiratory Disease Vaccine Market, By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine), Vaccine (MMR, PPSV23, DTaP, Respiratory Syncytial Virus (RSV), Haemophilus Influenzae Type B (Hib)), Disease Type (Tuberculosis, Pertussis, Influenza Virus, Streptococcus Pneumoniae (Pneumonia), Chronic Obstructive Pulmonary Disease (COPD), Diphtheria, Others), Age (Infant, Adolescent, Adult), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2030.
Respiratory Disease Vaccine Market Analysis and Size
Respiratory diseases are the diseases that affects and lungs and other parts of respiratory system. It is caused due to passive smoking, smoking tobacco, infection, asbestos and other kinds of air pollution. Chronic respiratory diseases are the diseases of airways and other structures of the lungs. The treatment of these diseases only reduces the symptoms. Immunization is the most effective method against chronic respiratory diseases.
Data Bridge Market Research analyses that the respiratory disease vaccine market which was USD 92.23 billion in 2022, is expected to reach USD 70.30 billion by 2030, and is expected to undergo a CAGR of 5.7% during the forecast period of 2023 to 2030. “Viral vaccine” dominates the type segment of the respiratory disease vaccine market owing to the rising prevalence of respiratory disorders. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Respiratory Disease Vaccine Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
|
|
Countries Covered
|
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
A vaccine against respiratory diseases is a sort of immunisation made to guard against infections brought on by pathogens that mostly affect the respiratory system. These vaccinations lower the chance of acquiring respiratory disorders by encouraging the immune system to recognise and defend against particular respiratory invaders, such as bacteria or viruses. They serve as a preventative strategy to lessen illness severity, consequences, and respiratory infection spread.
Respiratory Disease Vaccine Market Dynamics
Drivers
- Increasing Prevalence of Respiratory Diseases
There is a greater understanding of the need for respiratory disease vaccines as a result of the introduction of novel respiratory diseases such as the COVID-19 pandemic. This has increased funding for research and development of vaccinations to protect against both novel and old respiratory infection.
- Rising Government Initiatives
The development of new and improved vaccinations is supported by increased funding for research and development in the field of respiratory illness vaccines. The uptake of vaccines is increased via government-led vaccination campaigns and initiatives targeting vulnerable populations, such as children and the elderly.
Opportunities
- Growing Awareness Among the Population
Public awareness campaigns and educational efforts can enhance understanding of the benefits of respiratory disease vaccines, leading to higher vaccine acceptance rates.
- Rising Technological Advancements
Advances in vaccine technology, such as mRNA and viral vector platforms, offer opportunities to accelerate vaccine development and improve vaccine efficacy and safety.
Restrains/Challenges
- Strict Regulations
Meeting regulatory requirements for vaccine approval and licensure in different countries can be time-consuming and expensive, adding to the overall development costs.
- Logistics and Cold Chain Challenges
Some vaccines for respiratory diseases need to be kept and distributed in a cold chain, which can be difficult in areas with poor infrastructure and resources. Although it might be logistically challenging, maintaining the integrity of vaccinations during storage and transportation is essential.
- Complexity in Vaccine Development
The diversity of the pathogens involved (viruses, bacteria), and the infection’s ongoing evolution, make the development of vaccinations for respiratory disorders problematic. Increased expenses and extended development times may result from this complexity.
- Evolving Pathogens
The creation of novel strains and varieties is caused by the fast evolution of respiratory infections such as influenza viruses. This necessitates ongoing evaluation and revision of vaccination formulations, which can be time- and resource-consuming.
This respiratory disease vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the respiratory disease vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Respiratory Disease Vaccine Market Scope
The respiratory disease vaccine market is segmented on the basis of type, vaccine, disease type, age, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
Type
- Viral Vaccine
- Bacterial Vaccine
- Combination Vaccine
Vaccine
- MMR
- PPSV23
- DTaP
- Respiratory Syncytial Virus (RSV)
- Haemophilus Influenzae Type B (HIB)
Disease Type
- Tuberculosis
- Pertussis
- Influenza Virus
- Streptococcus Pneumoniae (Pneumonia)
- Chronic Obstructive Pulmonary Disease (COPD)
- Diphtheria
- Others
Age Group
- Infant
- Adolescent
- Adult
End-Users
- Clinic
- Hospital
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Respiratory Disease Vaccine Market Regional Analysis/Insights
Respiratory disease vaccine market is analyzed and market size information is provided by the type, vaccine, disease type, age, end-users and distribution channel as referenced above.
The countries covered in the respiratory disease vaccine market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa
North America dominates the respiratory disease vaccine market due to the presence of major key players, government support for R&D activities in the field of vaccination, high healthcare expenditure and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2023 to 2030 due to the increasing research and development activities, rising investment in the healthcare sector and high prevalence of respiratory diseases.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Respiratory disease vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. The data is available for historic period 2015 to 2020.
Competitive Landscape and Respiratory Disease Vaccine Market Share Analysis
Respiratory disease vaccine market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to respiratory disease vaccine market research.
Some of the major players operating in the respiratory disease vaccine market are:
- Bavarian Nordic (Denmark)
- Bayer AG (Switzerland)
- AstraZeneca (U.K.)
- Bio Farma (India)
- Dynavax Technologies (U.S.)
- Emergent BioSolutions Inc. (U.S.)
- Merck Sharp & Dohme Corp. (Japan)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Seqirus (U.K.)
- Sanofi (France)
- Serum Institute of India Pvt. Ltd. (India)
- CSL Limited (Australia)
- Novavax, Inc. (U.S.)
- INOVIO Pharmaceuticals (U.S.)
- Mitsubishi Tanabe Pharma Corporation (Japan)
SKU-